RECBIO-B: 2024 Annual Report

HKEXApr 22 07:49 ET · Announcements

Investors who bought high-level pharmaceutical Funds have hope! More than 80% of products achieved positive returns in the first quarter, and recovering losses is promising.

① A total of 264 medical Funds had positive returns in the first quarter of this year, accounting for over 80%, with many Funds achieving returns exceeding 15% this year. ② The net value of medical Funds established in 2020 and 2021 is currently being repaired, and investors who entered at high levels are expected to break even.

cls.cnApr 1 03:04 ET

Reikang Bio-B (02179) released its annual performance report, with a loss attributable to Shareholders of 0.562 billion yuan, narrowing by 1.67% year-on-year.

Reike Bio-B (02179) released its annual performance results for the year ended December 31, 2024, with other income of the group and...

Zhitong FinanceMar 28 08:04 ET

Express News | Jiangsu Recbio Technology FY Capex RMB 171.8 Million

ReutersMar 28 07:52 ET

RECBIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024ANDPROPOSED APPOINTMENT OF THE BOARD OBSERVER

HKEXMar 28 07:51 ET · Announcements

Reyko Biotechnology-B (02179.HK) plans to hold a Board of Directors meeting on March 28 to approve the annual performance.

Gelonghui announced on March 18 that the Board of Directors meeting for Reike Biological-B (02179.HK) will be held on March 28, 2025 (Friday) to review and approve the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its release, and to consider the distribution of a final dividend (if any).

Gelonghui FinanceMar 18 05:26 ET